Literature DB >> 16299306

Epitope-specific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins.

Jon Eric Tongren1, Patrick H Corran, William Jarra, Jean Langhorne, Eleanor M Riley.   

Abstract

Antibodies that bind to Fc receptors and activate complement are implicated in the efficient control of pathogens, but the processes that regulate their induction are still not well understood. To investigate antigen-dependent factors that regulate class switching, we have developed an in vivo model of class switching to immunoglobulin G2b (IgG2b) using the malaria antigen Plasmodium falciparum merozoite surface protein 2 (MSP2). C57BL/6 mice were immunized with recombinant proteins representing discrete domains of MSP2, and a T-cell epitope (C8) was identified within the conserved C terminus of the protein that preferentially induces IgG2b antibodies. The ability of C8 to induce IgG2b is ablated in both homozygous gamma interferon-negative and interleukin 10-negative mice. The IgG2b-inducing properties of C8 override the IgG1-inducing properties of both the fusion protein partner, glutathione S-transferase, and the adjuvant. Furthermore, when attached to other proteins that normally induce IgG1 responses, C8 induces a switch to IgG2b secretion. This is the first description of a defined T-cell epitope that drives specific IgG2b subclass switching, and our data offer proof of the concept that chimeric vaccines incorporating specific T-cell "switch epitopes" might be used to enhance qualitative aspects of the antibody response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299306      PMCID: PMC1307071          DOI: 10.1128/IAI.73.12.8119-8129.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

Review 1.  Immunoglobulin class switching.

Authors:  J Stavnezer
Journal:  Curr Opin Immunol       Date:  1996-04       Impact factor: 7.486

2.  A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

Authors:  A W Wheeler; J S Marshall; J T Ulrich
Journal:  Int Arch Allergy Immunol       Date:  2001-10       Impact factor: 2.749

Review 3.  Mechanism and regulation of immunoglobulin isotype switching.

Authors:  R L Coffman; D A Lebman; P Rothman
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum.

Authors:  J A Smythe; M G Peterson; R L Coppel; A J Saul; D J Kemp; R F Anders
Journal:  Mol Biochem Parasitol       Date:  1990-03       Impact factor: 1.759

6.  A hypothesis about the chronicity of malaria infection.

Authors:  P Druilhe; J L Pérignon
Journal:  Parasitol Today       Date:  1997-09

7.  Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.

Authors:  Wolfram G Metzger; Daniel M N Okenu; David R Cavanagh; Jane V Robinson; Kalifa A Bojang; Helen A Weiss; Jana S McBride; Brian M Greenwood; David J Conway
Journal:  Parasite Immunol       Date:  2003-06       Impact factor: 2.280

8.  Comparative study of the T cell response to two allelic forms of a malarial vaccine candidate protein.

Authors:  C M Rzepczyk; P A Csurhes; A J Saul; G L Jones; S Dyer; D Chee; N Goss; D O Irving
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

9.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

10.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  12 in total

1.  Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria.

Authors:  J Eric Tongren; Christopher J Drakeley; Suzanna L R McDonald; Hugh G Reyburn; Alphaxard Manjurano; Watoky M M Nkya; Martha M Lemnge; Channe D Gowda; Jim E Todd; Patrick H Corran; Eleanor M Riley
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 2.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

3.  Nutrient Deficiencies and Potential Alteration in Plasma Levels of Naturally Acquired Malaria-Specific Antibody Responses in Tanzanian Children.

Authors:  Erasto V Mbugi; Gerco den Hartog; Jacobien Veenemans; Jaffu O Chilongola; Hans Verhoef; Huub F J Savelkoul
Journal:  Front Nutr       Date:  2022-06-17

4.  Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children.

Authors:  Jo-Anne Chan; Jessica R Loughland; Lauren de la Parte; Satomi Okano; Isaac Ssewanyana; Mayimuna Nalubega; Felistas Nankya; Kenneth Musinguzi; John Rek; Emmanuel Arinaitwe; Peta Tipping; Peter Bourke; Dean Andrew; Nicholas Dooley; Arya SheelaNair; Bruce D Wines; P Mark Hogarth; James G Beeson; Bryan Greenhouse; Grant Dorsey; Moses Kamya; Gunter Hartel; Gabriela Minigo; Margaret Feeney; Prasanna Jagannathan; Michelle J Boyle
Journal:  Nat Commun       Date:  2022-07-18       Impact factor: 17.694

Review 5.  How B cells shape the immune response against Mycobacterium tuberculosis.

Authors:  Paul J Maglione; John Chan
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

6.  Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.

Authors:  Danielle I Stanisic; Jack S Richards; Fiona J McCallum; Pascal Michon; Christopher L King; Sonja Schoepflin; Paul R Gilson; Vincent J Murphy; Robin F Anders; Ivo Mueller; James G Beeson
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

7.  A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

Authors:  James S McCarthy; Joanne Marjason; Suzanne Elliott; Paul Fahey; Gilles Bang; Elissa Malkin; Eveline Tierney; Hayley Aked-Hurditch; Christopher Adda; Nadia Cross; Jack S Richards; Freya J I Fowkes; Michelle J Boyle; Carole Long; Pierre Druilhe; James G Beeson; Robin F Anders
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

8.  Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.

Authors:  Sumi Biswas; Prateek Choudhary; Sean C Elias; Kazutoyo Miura; Kathryn H Milne; Simone C de Cassan; Katharine A Collins; Fenella D Halstead; Carly M Bliss; Katie J Ewer; Faith H Osier; Susanne H Hodgson; Christopher J A Duncan; Geraldine A O'Hara; Carole A Long; Adrian V S Hill; Simon J Draper
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

9.  Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.

Authors:  Bankala Krishnarjuna; Dean Andrew; Christopher A MacRaild; Rodrigo A V Morales; James G Beeson; Robin F Anders; Jack S Richards; Raymond S Norton
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

10.  Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort.

Authors:  N O Duah; D J C Miles; H C Whittle; D J Conway
Journal:  Parasite Immunol       Date:  2010-02       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.